NCT00002210
Completed
Phase 2
Phase II Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Effect of Delavirdine Mesylate (Rescriptor), in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1-Infected Neonates, Infants, and Children
Pharmacia and Upjohn1 site in 1 country24 target enrollmentAugust 31, 2001
ConditionsHIV Infections
DrugsDelavirdine mesylate
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- Pharmacia and Upjohn
- Enrollment
- 24
- Locations
- 1
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3HIV InfectionsNCT00002123Pharmacia and Upjohn
Completed
Phase 1
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)HIV InfectionsNCT00000810National Institute of Allergy and Infectious Diseases (NIAID)120
Completed
Not Applicable
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected PatientsHIV InfectionsNCT00002401Pharmacia and Upjohn160
Completed
Not Applicable
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take ZidovudineHIV InfectionsNCT00002312Pharmacia and Upjohn
Terminated
Phase 1
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung CancerNSCLCNCT05492045InventisBio Co., Ltd22